{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AML+%28Acute+Myelogenous+Leukemia%29&page=34",
    "query": {
      "condition": "AML (Acute Myelogenous Leukemia)",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 2378,
    "total_pages": 238,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AML+%28Acute+Myelogenous+Leukemia%29&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AML+%28Acute+Myelogenous+Leukemia%29&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T03:35:41.707Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01221857",
      "title": "Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia (ALL)",
        "Acute Myelogenous Leukemia (AML)",
        "Myelodysplastic Syndrome (MDS)",
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Disease"
      ],
      "interventions": [
        {
          "name": "NiCord®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gamida Cell ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "8 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-11",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2021-08-03",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 2,
      "location_summary": "Maywood, Illinois • Durham, North Carolina",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01221857"
    },
    {
      "nct_id": "NCT00896701",
      "title": "Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 451,
      "start_date": "2004-01",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2016-07-13",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 2,
      "location_summary": "Kinston, North Carolina • Columbus, Ohio",
      "locations": [
        {
          "city": "Kinston",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00896701"
    },
    {
      "nct_id": "NCT01397799",
      "title": "Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "KX2-391",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kinex Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-12",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2015-12-07",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 3,
      "location_summary": "Buffalo, New York • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397799"
    },
    {
      "nct_id": "NCT00814164",
      "title": "Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "clofarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cytogenetic analysis",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "60 Years to 120 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-12",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2016-08-17",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00814164"
    },
    {
      "nct_id": "NCT06548230",
      "title": "A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome(MDS)",
        "Acute Myelogenous Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Nadunolimab",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-03-05",
      "completion_date": "2029-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06548230"
    },
    {
      "nct_id": "NCT07254793",
      "title": "Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoid Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Undifferentiated Leukemia (AUL)",
        "Myelodysplastic Syndrome",
        "Chronic Myeloid Leukemia",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Exercise Mobilized Prophylactic DLI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Prophylactic DLI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Exercise Mobilized Therapeutic DLI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Therapeutic DLI",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 94,
      "start_date": "2026-10-31",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07254793"
    },
    {
      "nct_id": "NCT00047021",
      "title": "Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 3,
      "start_date": "2001-11",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047021"
    },
    {
      "nct_id": "NCT00129948",
      "title": "Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "Troxatyl™ (troxacitabine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SGX Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2005-07",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2006-11-03",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00129948"
    },
    {
      "nct_id": "NCT03904251",
      "title": "CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Gemtuzumab Ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "Liposome-encapsulated Daunorubicin-Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2019-07-18",
      "completion_date": "2023-10-25",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03904251"
    },
    {
      "nct_id": "NCT01200355",
      "title": "Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "micafungin",
          "type": "DRUG"
        },
        {
          "name": "posaconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2010-09-09",
      "completion_date": "2018-04-03",
      "has_results": true,
      "last_update_posted_date": "2018-05-07",
      "last_synced_at": "2026-10-17T03:35:41.707Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01200355"
    }
  ]
}